CoChat

Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19

Open access

Preprint — published as 10.7554/elife.83201

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Background: There is no generally accepted methodology for in vivo assessment of antiviral activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment of COVID-19, but whether it has significant antiviral activity in vivo is uncertain. Methods: In a multicentre open label, randomized, controlled adaptive platform trial, adult patients with early symptomatic COVID-19 were randomized to one of six treatment arms including high dose ivermectin (600µg/kg daily for seven days), the monoclonal antibodies casirivimab and imdevimab (600mg/600mg), and no study drug. Viral clearance rates were derived from daily duplicate oropharyngeal quantitative PCR measurements. This ongoing trial is registered at ClinicalTrials.gov ( NCT05041907 ). Results: Randomization to the ivermectin arm was stopped after enrolling 205 patients into all arms, as the prespecified futility threshold was reached. Compared with the no study drug arm, the mean estimated SARS-CoV-2 viral clearance following ivermectin was 9.1% slower [95%CI -27.2% to +11.8%; n=45 versus n=41], whereas in a preliminary analysis of the casirivimab/imdevimab arm it was 52.3% faster [95%CI +7.0% to +115.1%; n=10 (Delta variant) versus n=41]. Conclusions: High dose ivermectin did not have measurable antiviral activity in early symptomatic COVID-19. Measured in this way viral clearance rate is a valuable pharmacodynamic measure in assessing antiviral COVID-19 therapeutics in vivo . Funding: “Finding treatments for COVID-19: A phase 2 multi-centre adaptive platform trial to assess antiviral pharmacodynamics in early symptomatic COVID-19 (PLAT-COV)” is funded by the Wellcome Therapeutics Accelerator (223195/Z/21/Z). Impact: Rate of viral clearance determined from daily duplicate oropharyngeal swabs over one week is an efficient measure of antiviral efficacy in early COVID-19 infection. High dose ivermectin did not demonstrate measurable antiviral activity in early symptomatic COVID-19 infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2022.07.15.22277570

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Summary of patient characteristics included in the mITT population (n=96). Study CONSORT diagram for the ivermectin analysis. *Prescreening occurred in the hospitals’ Acute Respiratory Infection (ARI) units. Potentially eligible participants (based on age, duration of symptoms, reported comorbidities, and a willingness to consider study participation) were selected by the ARI Nurses to be contacted by the study team. As a result, a high proportion of those assessed for eligibility participated in the study. **SARS CoV-2 Antigen Test Kit (STANDARD Q COVID-19 Ag Test, SD Biosensor, Suwon-si, Republic of Korea). mITT, modified intention-to-treat.
Figure 1. Summary of patient characteristics included in the mITT population (n=96). Study CONSORT diagram for the ivermectin analysis. *Prescreening occurred in the hospitals’ Acute Respiratory Infection (ARI) units. Potentially eligible participants (based on age, duration of symptoms, reported comorbidities, and a willingness to consider study participation) were selected by the ARI Nurses to be contacted by the study team. As a result, a high proportion of those assessed for eligibility participated in the study. **SARS CoV-2 Antigen Test Kit (STANDARD Q COVID-19 Ag Test, SD Biosensor, Suwon-si, Republic of Korea). mITT, modified intention-to-treat.CC BY · PubMed Central
Figure 1—figure supplement 1. Randomization dates and virus variants of all patients with available PCR data (n=99). This excludes two patients: one who had no detectable virus (likely an enrolment error); and one who left the study following randomization (no swabs were taken). All patients included in the analysis had their virus genotyped (none were imputed).
Figure 1—figure supplement 1. Randomization dates and virus variants of all patients with available PCR data (n=99). This excludes two patients: one who had no detectable virus (likely an enrolment error); and one who left the study following randomization (no swabs were taken). All patients included in the analysis had their virus genotyped (none were imputed).CC BY · PubMed Central
Figure 2. Summary of oropharyngeal viral load data in the analysis data set (n=96). (a) Distribution of viral loads at randomization (median of 4 swabs per patient). (b) Individual serial viral load data with x-axis jitter. Median values by study arm are overlaid. The day 14 samples are not used in the primary analysis.
Figure 2. Summary of oropharyngeal viral load data in the analysis data set (n=96). (a) Distribution of viral loads at randomization (median of 4 swabs per patient). (b) Individual serial viral load data with x-axis jitter. Median values by study arm are overlaid. The day 14 samples are not used in the primary analysis.CC BY · PubMed Central
Figure 3. Predicted ivermectin plasma concentrations over time under the population PK model fit to data from healthy volunteers (Kobylinski et al., 2020), and the ivermectin patients in the PLATCOV study. Mean predicted concentrations with 80% and 95% confidence intervals are shown for daily dosing of 600 μg/kg ivermectin in a 70 kg adult over 1 week for patients (thick line) and healthy volunteers (dashed line). The mean relative bioavailability in patients compared to healthy volunteers was estimated as 2.6.
Figure 3. Predicted ivermectin plasma concentrations over time under the population PK model fit to data from healthy volunteers (Kobylinski et al., 2020), and the ivermectin patients in the PLATCOV study. Mean predicted concentrations with 80% and 95% confidence intervals are shown for daily dosing of 600 μg/kg ivermectin in a 70 kg adult over 1 week for patients (thick line) and healthy volunteers (dashed line). The mean relative bioavailability in patients compared to healthy volunteers was estimated as 2.6.CC BY · PubMed Central
Figure 4. Treatment effects mean posterior estimates of the differences in the rate of viral clearance (thick dots) compared to the no study drug arm. 80% (thick lines) and 95% (thin lines) credible intervals under three hierarchical Bayesian models are shown. The gray area shows the futility zone (<12.5% increase in the rate of viral clearance). Results from three models are shown. The main model used to report effect estimates in the text is the linear model (red).
Figure 4. Treatment effects mean posterior estimates of the differences in the rate of viral clearance (thick dots) compared to the no study drug arm. 80% (thick lines) and 95% (thin lines) credible intervals under three hierarchical Bayesian models are shown. The gray area shows the futility zone (<12.5% increase in the rate of viral clearance). Results from three models are shown. The main model used to report effect estimates in the text is the linear model (red).CC BY · PubMed Central
Figure 4—figure supplement 1. Covariate effects estimated for the main analytical linear model.
Figure 4—figure supplement 1. Covariate effects estimated for the main analytical linear model.CC BY · PubMed Central
Figure 4—figure supplement 2. Covariate effects on the intercept and slope. Covariate effects on intercept (left) and slope (right) for the linear model with additional covariate adjustment.
Figure 4—figure supplement 2. Covariate effects on the intercept and slope. Covariate effects on intercept (left) and slope (right) for the linear model with additional covariate adjustment.CC BY · PubMed Central
Figure 4—figure supplement 3. Treatment effect estimates for all nine models fit to the data. Circles/triangles show the mean posterior estimates (circles: linear models; triangles: nonlinear models); thick lines: 80% credible intervals; thin lines: 95% credible intervals. A description of each model is given in the Statistical analysis section above.
Figure 4—figure supplement 3. Treatment effect estimates for all nine models fit to the data. Circles/triangles show the mean posterior estimates (circles: linear models; triangles: nonlinear models); thick lines: 80% credible intervals; thin lines: 95% credible intervals. A description of each model is given in the Statistical analysis section above.CC BY · PubMed Central
Figure 5. Individual patient virus clearance half-life estimates over time. The individual oropharyngeal virus clearance half-life mean posterior estimates with 95% credible intervals (lines) are shown (squares/circles/triangles corresponding to the virus genotype: temporarily Delta, Omicron BA.1, Omicron BA.2, respectively). The model estimated mean clearance half-life (95%CI) in untreated patients is shown by the grey line (dashed line-shaded area).
Figure 5. Individual patient virus clearance half-life estimates over time. The individual oropharyngeal virus clearance half-life mean posterior estimates with 95% credible intervals (lines) are shown (squares/circles/triangles corresponding to the virus genotype: temporarily Delta, Omicron BA.1, Omicron BA.2, respectively). The model estimated mean clearance half-life (95%CI) in untreated patients is shown by the grey line (dashed line-shaded area).CC BY · PubMed Central
Figure 5—figure supplement 1. Estimated clearance half-lives in all patients in the mITT population (n=96), grouped by treatment arm and in order of decreasing rate of clearance. The mean posterior estimated virus clearance half-lives are shown by the squares/circles/triangles (corresponding to the Delta, BA.1, and BA.2 variants, respectively). The vertical dashed line shows the posterior mean population virus clearance half-life (the gray shaded area is the 95% credible interval).
Figure 5—figure supplement 1. Estimated clearance half-lives in all patients in the mITT population (n=96), grouped by treatment arm and in order of decreasing rate of clearance. The mean posterior estimated virus clearance half-lives are shown by the squares/circles/triangles (corresponding to the Delta, BA.1, and BA.2 variants, respectively). The vertical dashed line shows the posterior mean population virus clearance half-life (the gray shaded area is the 95% credible interval).CC BY · PubMed Central
Figure 5—figure supplement 2. Individual fits to the serial qPCR data under the two main Bayesian hierarchical models (pink: linear model with RNase P adjustment; green: nonlinear model with RNase P adjustment). Lines show mean fits; shaded areas show 95% credible intervals around fits. Black circles show viral load measurements for each independent swab. Only follow-up data included in the mITT analysis data set are shown (e.g., for patients who switched medication after day 2, we only show data up until the switch, i.e., the data that were used for the analysis). Site codes: TH1=HTD, TH57=BP, TH58=VJ.
Figure 5—figure supplement 2. Individual fits to the serial qPCR data under the two main Bayesian hierarchical models (pink: linear model with RNase P adjustment; green: nonlinear model with RNase P adjustment). Lines show mean fits; shaded areas show 95% credible intervals around fits. Black circles show viral load measurements for each independent swab. Only follow-up data included in the mITT analysis data set are shown (e.g., for patients who switched medication after day 2, we only show data up until the switch, i.e., the data that were used for the analysis). Site codes: TH1=HTD, TH57=BP, TH58=VJ.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 22

Metadata

Authors
Schilling, W. H., Jittamala, P., Watson, J. A., Ekkapongpisit, M., Siripoon, T., Ngamprasertchai, T., Luvira, V., Pongwilai, S., Cruz, C., Callery, J. J., Boyd, S., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M. Y., Piaraksa, N., Suwannasin, K., Hanboonkunupakarn, P., Hanboonkunupakarn, B., Sookprome, S., Poovorawan, K., Thaipadungpanit, J., Blacksell, S., Imwong, M., Tarning, J., Taylor, W. R., Chotivanich, V., Sangketchon, C., Ruksakul, W., Chotivanich, K., Teixeira, M. M., Pukrittayakamee, S., Dondorp, A. M., Day, N. P., Piyaphanee, W., Phumratanaprapin, W., & White, N. J.
Affiliations
  • Mahidol University (TH)
  • Navamindradhiraj University (TH)
  • Universidade Federal de Minas Gerais (BR)
Corresponding author
  • Schilling, William HK
  • White, Nicholas J
Venue
eLife
Publisher
openRxiv
Published
2022-07-19
Volume
12
ISSN
2050-084X (ISSN-L)
OpenAlex
W4321366419
Cited by
22
References
19
Citations by year
2026: 2 · 2025: 6 · 2024: 8 · 2023: 4 · 2022: 2
FWCI
4.12
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • eLife (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
  • Wellcome Trust (223195/Z/21/Z)
  • Connecticut Sea Grant, University of Connecticut
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords
ivermectin, SARS-CoV-2, COVID-19 pandemic, antiviral activity, pharmacometrics, casirivimab, imdevimab, adaptive platform trial, Delta variant, futility of treatment, pharmacodynamics
MeSH terms
COVID-19, SARS-CoV-2, Adult, Antiviral Agents, Humans, Ivermectin, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19. https://app.cochat.ai/papers/10.1101/2022.07.15.22277570
The paper
Schilling, W. H., Jittamala, P., Watson, J. A., Ekkapongpisit, M., Siripoon, T., Ngamprasertchai, T., Luvira, V., Pongwilai, S., Cruz, C., Callery, J. J., Boyd, S., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M. Y., Piaraksa, N., Suwannasin, K., Hanboonkunupakarn, P., Hanboonkunupakarn, B., . . . White, N. J. (2022). Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19. eLife. https://doi.org/10.1101/2022.07.15.22277570

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.